Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

Science Translational Medicine

Volumn 8, Issue 368, 2016, Pages

  Rosenblatt, Jacalyn ^a   Stone, Richard M ^b   Uhl, Lynne ^a   Neuberg, Donna ^b   Joyce, Robin ^a   Levine, James D ^a   Arnason, Jon ^a   McMasters, Malgorzata ^a   Luptakova, Katarina ^a   Jain, Salvia ^a   Zwicker, Jeffrey I ^a   Hamdan, Ayad ^a   Boussiotis, Vassiliki ^a   Steensma, David P ^b   DeAngelo, Daniel J ^b   Galinsky, Ilene ^b   Dutt, Poorvi Somaiya ^a   Logan, Emma ^a   Bryant, Mary Paty ^a   Stroopinsky, Dina ^a   Werner, Lillian ^b   Palmer, Kristen ^a   Coll, Max ^a   Washington, Abigail ^a   Cole, Leandra ^a   Kufe, Donald ^b   Avigan, David ^a   more..

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CANCER VACCINE; CYTARABINE; DECITABINE; DENDRITIC CELL VACCINE; LEUKEMIA ANTIGEN; THYROTROPIN; ANTINEOPLASTIC AGENT; TUMOR ANTIGEN;

ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; ADVERSE DRUG REACTION; AGED; ANTIGEN SPECIFICITY; APPLICATION SITE INFLAMMATION; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CELL EXPANSION; CELL FUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG MEGADOSE; DRUG TOLERABILITY; EOSINOPHILIA; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDOMA; IMMUNOSTIMULATION; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MONOCYTE; MULTIPLE CYCLE TREATMENT; MYALGIA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PRURITUS; SKIN INDURATION; T LYMPHOCYTE; THROMBOCYTOPENIA; TUMOR IMMUNITY; URTICARIA; VACCINE PRODUCTION; ACUTE MYELOID LEUKEMIA; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; REGULATORY T LYMPHOCYTE; REMISSION; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; FEMALE; HUMANS; IMMUNE SYSTEM; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REMISSION INDUCTION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VACCINATION;

EID: 85003666716     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag1298     Document Type: Article

References (27)

1. R. J. Mayer, R. B. Davis, C. A. Schiffer, D. T. Berg, B. L. Powell, P. Schulman, G. A. Omura, J. O. Moore, O. Ross McIntyre, E. Frei; Cancer and Leukemia Group B, Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331, 896-903 (1994).
2. R. Champlin, Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. Best Pract. Res. Clin. Haematol. 26, 297-300 (2013).
3. C. Kahl, R. Krahl, C. Becker, H. K. Al-Ali, H. G. Sayer, A. Schulze, M. Herold, M. Hänel, S. Scholl, A. Hochhaus, L. Uharek, G. Maschmeyer, D. Haehling, C. Junghanß, N. Peter, D. Kämpfe, E. Kettner, T. Heinicke, T. Fischer, U. Kreibich, H.-H. Wolf, D. Niederwiese, Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: A study of the East German Haematology and Oncology Study Group (OSHO). J. Cancer Res. Clin. Oncol. 142, 305-315 (2016).
4. A. H. Goldstone, A. K. Burnett, K. Wheatley, A. G. Smith, R. Michael Hutchinson, R. E. Clark, Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 98, 1302-1311 (2001).
5. J. O. Moore, S. L. George, R. K. Dodge, P. C. Amrein, B. L. Powell, J. E. Kolitz, M. R. Baer, F. R. Davey, C. D. Bloomfield, R. A. Larson, C. A. Schiffer, Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105, 3420-3427 (2005).
6. J. Gong, S. Koido, Y. Kato, Y. Tanaka, D. Chen, A. Jonas, I. Galinsky, D. DeAngelo, D. Avigan, D. Kufe, R. Stone, Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res. 28, 1303-1312 (2004).
7. J. Gong, D. Avigan, D. Chen, Z. Wu, S. Koido, M. Kashiwaba, D. Kufe, Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 97, 2715-2718 (2000).
8. J. Gong, D. Chen, M. Kashiwaba, D. Kufe, Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3, 558-561 (1997).
9. J. Gong, D. Chen, M. Kashiwaba, Y. Li, L. Chen, H. Takeuchi, H. Qu, G. J. Rowse, S. J. Gendler, D. Kufe, Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 95, 6279-6283 (1998).
10. J. Rosenblatt, I. Avivi, B. Vasir, L. Uhl, N. C. Munshi, T. Katz, B. R. Dey, P. Somaiya, H. Mills, F. Campigotto, E. Weller, R. Joyce, J. D. Levine, D. Tzachanis, P. Richardson, J. Laubach, N. Raje, V. Boussiotis, Y. E. Yuan, L. Bisharat, V. Held, J. Rowe, K. Anderson, D. Kufe, D. Avigan, Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19, 3640-3648 (2013).
11. J. Rosenblatt, B. Vasir, L. Uhl, S. Blotta, C. MacNamara, P. Somaiya, Z. Wu, R. Joyce, J. D. Levine, D. Dombagoda, Y. E. Yuan, K. Francoeur, D. Fitzgerald, P. Richardson, E. Weller, K. Anderson, D. Kufe, N. Munshi, D. Avigan, Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117, 393-402 (2011).
12. H. Döhner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Büchner, A. K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R. A. Larson, F. Lo-Coco, T. Naoe, D. Niederwieser, G. J. Ossenkoppele, M. A. Sanz, J. Sierra, M. S. Tallman, B. Löwenberg, C. D. Bloomfield, Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474 (2010).
13. J. Brayer, J. E. Lancet, J. Powers, A. List, L. Balducci, R. Komrokji, J. Pinilla-Ibarz, WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am. J. Hematol. 90, 602-607 (2015).
14. A. Di Stasi, A. M. Jimenez, K. Minagawa, M. Al-Obaidi, K. Rezvania, Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front. Immunol. 6, 36 (2015).
15. M. Subklewe, C. Geiger, F. S. Lichtenegger, M. Javorovic, G. Kvalheim, D. J. Schendel, I. Bigalke, New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol. Immunother. 63, 1093-1103 (2014).
16. V. F. Van Tendeloo, A. Van de Velde, A. Van Driessche, N. Cools, S. Anguille, K. Ladell, E. Gostick, K. Vermeulen, K. Pieters, G. Nijs, B. Stein, E. L. Smits, W. A. Schroyens, A. P. Gadisseur, I. Vrelust, P. G. Jorens, H. Goossens, I. J. de Vries, D. A. Price, Y. Oji, Y. Oka, H. Sugiyama, Z. N. Berneman, Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. U.S.A. 107, 13824-13829 (2010).
17. V. Vogt, J. Schick, C. Ansprenger, M. Braeu, T. Kroell, D. Kraemer, C.-H. Köhne, A. Hausmann, R. Buhmann, J. Tischer, H. Schmetzer, Profiles of activation, differentiation-markers, or b-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells. J. Immunother. 37, 331-347 (2014).
18. Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, N. Hosen, S. Yoshihara, F. Wu, F. Fujiki, M. Murakami, T. Masuda, S. Nishida, T. Shirakata, S. Nakatsuka, A. Sasaki, K. Udaka, H. Dohy, K. Aozasa, S. Noguchi, I. Kawase, H. Sugiyama, Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. U.S.A. 101, 13885-13890 (2004).
19. M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Götz, M. Heyduk, G. Ritter, D. E. Speiser, S. Gnjatic, P. Guillaume, M. Ringhoffer, R. F. Schlenk, P. Liebisch, D. Bunjes, H. Shiku, H. Dohner, J. Greiner, RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111, 1357-1365 (2008).
20. U. Keilholz, A. Letsch, A. Busse, A.M. Asemissen, S. Bauer, I.W. Blau, W.-K. Hofmann, L. Uharek, E. Thiel, C. Scheibenbogen, A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113, 6541-6548 (2009).
21. S. L. Maude, D. T. Teachey, D. L. Porter, S. A. Grupp, CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017-4023 (2015).
22. D. Stroopinsky, J. Rosenblatt, K. Ito, H. Mills, L. Yin, H. Rajabi, B. Vasir, T. Kufe, K. Luptakova, J. Arnason, C. Nardella, J.D. Levine, R. M. Joyce, I. Galinsky, Y. Reiter, R.M. Stone, P.P. Pandolfi, D. Kufe, D. Avigan, MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 73, 5569-5579 (2013).
23. S. L. Topalian, F. Stephen Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
24. D. L. Porter, W.-T. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw, A. W. Loren, A. Bagg, K. T. Marcucci, A. Shen, V. Gonzalez, D. Ambrose, S. A. Grupp, A. Chew, Z. Zheng, M. C. Milone, B. L. Levine, J. J. Melenhorst, C. H. June, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
25. D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, S. M. Steinberg, D. Stroncek, N. Tschernia, C. Yuan, H. Zhang, L. Zhang, S. A. Rosenberg, A. S. Wayne, C. L. Mackall, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
26. + T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117, 4501-4510 (2011).
27. D. Kufe, G. Inghirami, M. Abe, D. Hayes, H. Justi-Wheeler, J. Schlom, Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3, 223-232 (1984).